These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 12807821)

  • 21. Impact of VIP and cAMP on the regulation of TNF-alpha and IL-10 production: implications for rheumatoid arthritis.
    Foey AD; Field S; Ahmed S; Jain A; Feldmann M; Brennan FM; Williams R
    Arthritis Res Ther; 2003; 5(6):R317-28. PubMed ID: 14680506
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The effects of a novel phosphodiesterase 7A and -4 dual inhibitor, YM-393059, on T-cell-related cytokine production in vitro and in vivo.
    Yamamoto S; Sugahara S; Naito R; Ichikawa A; Ikeda K; Yamada T; Shimizu Y
    Eur J Pharmacol; 2006 Jul; 541(1-2):106-14. PubMed ID: 16780833
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Regulation of interleukin-13 by type 4 cyclic nucleotide phosphodiesterase (PDE) inhibitors in allergen-specific human T lymphocyte clones.
    Essayan DM; Kagey-Sobotka A; Lichtenstein LM; Huang SK
    Biochem Pharmacol; 1997 Apr; 53(7):1055-60. PubMed ID: 9174120
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evidence that cyclic AMP phosphodiesterase inhibitors suppress TNF alpha generation from human monocytes by interacting with a 'low-affinity' phosphodiesterase 4 conformer.
    Souness JE; Griffin M; Maslen C; Ebsworth K; Scott LC; Pollock K; Palfreyman MN; Karlsson JA
    Br J Pharmacol; 1996 Jun; 118(3):649-58. PubMed ID: 8762090
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Interleukin-10 does not mediate the inhibitory effect of PDE-4 inhibitors and other cAMP-elevating drugs on lipopolysaccharide-induced tumors necrosis factor-alpha generation from human peripheral blood monocytes.
    Seldon PM; Barnes PJ; Giembycz MA
    Cell Biochem Biophys; 1998; 29(1-2):179-201. PubMed ID: 9631245
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Differential efficacy of lymphocyte- and monocyte-selective pretreatment with a type 4 phosphodiesterase inhibitor on antigen-driven proliferation and cytokine gene expression.
    Essayan DM; Huang SK; Kagey-Sobotka A; Lichtenstein LM
    J Allergy Clin Immunol; 1997 Jan; 99(1 Pt 1):28-37. PubMed ID: 9003208
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Specific role of phosphodiesterase 4B in lipopolysaccharide-induced signaling in mouse macrophages.
    Jin SL; Lan L; Zoudilova M; Conti M
    J Immunol; 2005 Aug; 175(3):1523-31. PubMed ID: 16034090
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Regulation of distinct cyclic AMP-specific phosphodiesterase (phosphodiesterase type 4) isozymes in human monocytic cells.
    Verghese MW; McConnell RT; Lenhard JM; Hamacher L; Jin SL
    Mol Pharmacol; 1995 Jun; 47(6):1164-71. PubMed ID: 7603456
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phosphodiesterase 4 inhibitors augment levels of glucocorticoid receptor in B cell chronic lymphocytic leukemia but not in normal circulating hematopoietic cells.
    Meyers JA; Taverna J; Chaves J; Makkinje A; Lerner A
    Clin Cancer Res; 2007 Aug; 13(16):4920-7. PubMed ID: 17699872
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In vitro differentiation of human monocytes to macrophages: change of PDE profile and its relationship to suppression of tumour necrosis factor-alpha release by PDE inhibitors.
    Gantner F; Kupferschmidt R; Schudt C; Wendel A; Hatzelmann A
    Br J Pharmacol; 1997 May; 121(2):221-31. PubMed ID: 9154331
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Characterization of the phosphodiesterase (PDE) pattern of in vitro-generated human dendritic cells (DC) and the influence of PDE inhibitors on DC function.
    Gantner F; Schudt C; Wendel A; Hatzelmann A
    Pulm Pharmacol Ther; 1999; 12(6):377-86. PubMed ID: 10587479
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of the phosphodiesterase IV inhibitor rolipram on Th1 and Th2 immune responses in mice.
    Yamaki K; Li X; Uchida H; Alam AH; Hossain MA; Yanagisawa R; Takano H; Taneda S; Hayashi H; Mori Y; Yoshino S
    J Pharm Pharmacol; 2004 Jul; 56(7):877-82. PubMed ID: 15233866
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Rolipram attenuates bile duct ligation-induced liver injury in rats: a potential pathogenic role of PDE4.
    Gobejishvili L; Barve S; Breitkopf-Heinlein K; Li Y; Zhang J; Avila DV; Dooley S; McClain CJ
    J Pharmacol Exp Ther; 2013 Oct; 347(1):80-90. PubMed ID: 23887098
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Modulation of cell adhesion molecule expression and function on human lung microvascular endothelial cells by inhibition of phosphodiesterases 3 and 4.
    Blease K; Burke-Gaffney A; Hellewell PG
    Br J Pharmacol; 1998 May; 124(1):229-37. PubMed ID: 9630364
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of nonselective and isozyme selective cyclic nucleotide phosphodiesterase inhibitors on antigen-induced cytokine gene expression in peripheral blood mononuclear cells.
    Essayan DM; Huang SK; Kagey-Sobotka A; Lichtenstein LM
    Am J Respir Cell Mol Biol; 1995 Dec; 13(6):692-702. PubMed ID: 7576707
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of ciclamilast, a new PDE 4 PDE4 inhibitor, on airway hyperresponsiveness, PDE4D expression and airway inflammation in a murine model of asthma.
    Deng YM; Xie QM; Tang HF; Sun JG; Deng JF; Chen JQ; Yang SY
    Eur J Pharmacol; 2006 Oct; 547(1-3):125-35. PubMed ID: 16956605
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Behavioural effects of selective PDE4 inhibitors in relation to inhibition of catalytic activity and competition for [3H]rolipram binding.
    Kapui Z; Bence J; Boronkay E; Mikus E; Urbán Szabó K; Baranyi A; Arányi P
    Neurobiology (Bp); 1999; 7(1):71-3. PubMed ID: 10746252
    [No Abstract]   [Full Text] [Related]  

  • 38. Comparison of alpha-Type-1 polarizing and standard dendritic cell cytokine cocktail for maturation of therapeutic monocyte-derived dendritic cell preparations from cancer patients.
    Trepiakas R; Pedersen AE; Met O; Hansen MH; Berntsen A; Svane IM
    Vaccine; 2008 Jun; 26(23):2824-32. PubMed ID: 18450338
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of PDE4 inhibitors on zymosan-induced IL-8 release from human neutrophils: synergism with prostanoids and salbutamol.
    Au BT; Teixeira MM; Collins PD; Williams TJ
    Br J Pharmacol; 1998 Mar; 123(6):1260-6. PubMed ID: 9559913
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impaired host defense to Klebsiella pneumoniae infection in mice treated with the PDE4 inhibitor rolipram.
    Soares AC; Souza DG; Pinho V; Vieira AT; Barsante MM; Nicoli JR; Teixeira M
    Br J Pharmacol; 2003 Nov; 140(5):855-62. PubMed ID: 14585803
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.